Keywords: Astellas, Medivation, Prostate cancer, MDV3100
Astellas and Medivation see strong Ph I/II data on prostate cancer drug candidate MDV3100
Article | 16 April 2010
US firm Medivation and Japan’s Astellas Pharma, with which it entered into a $765 million licensing deal last fall, have ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
